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ABSTRACT 
Objective:  DLBS0533 extract is a bioactive fraction obtained from combination of Phaleria macrocarpa and Nigella sativa. This present study aims 
to observe its potentially anti-inflammatory activities using carragenaan-induced paw edema in mice as animal model. 
Methods:  Mice were divided into control, positive control and dose groups. Diclofenac potassium was used as a positive control. Treatment 
DLBS0533 was given at dose 39, 78 and 156 mg/kg body weight (b. w.). Edema thickness was examined for 6 hours.  
Results:  Reduction in edema is shown in 27.26%; 30.71% and 32.72% at dose of 39, 78 and 156 mg/kg b. w., respectively. Comparation between 
dose groups and positive control group show that dose 156 mg/kg b. w. did not give significantly different. Therefore, dose 39 and 78 mg/kg b. w. 
also gave anti-inflammatory activities proved by reduction in edema.  
Conclusions:  Taken together, DLBS0533 potentially have anti-inflammatory activities.  
Keywords:  DLBS0533, Anti-inflammation, Mice, Edema, Carragenan. 
 
INTRODUCTION 
Inflammation is the body response from injury of cells and tissues 
due to different insulting factor, such as infection, chemical, thermal 
and mechanical factors [1]. Joint pain and swelling, related to 
arthritis or other diseases are disorders commonly associated with 
inflammation. Inflammation drugs can be grouped into steroidal and 
non-steroidal anti-inflammatory drugs (NSAIDs). The most widely 
used medicine between the two groups for the treatment of 
inflammation-related disorders is NSAIDs. It acts primarily by 
inhibition cyclooxygenase (COX) pathway. Specifically it inhibits 
arachidonic acid metabolism into prostaglandins. Diclofenac 
potassium is one of NSAIDs which works non-selectively by 
inhibiting COX-1 and COX-2 [2]. 
Bioactive fraction DLBS0533 is fractionated from Phaleria 
macrocarpa and Nigella sativa. P. macrocarpa, commonly known in 
Indonesia as “mahkota dewa”, is a plant originated from Papua 
Island, Indonesia and grows in many Indonesian areas. Traditionally, 
this plant has been used as anti-microbial, anti-fungal, anti-diabetic, 
anti-inflammatory and many more [3]. In addition, extract of P. 
macrocarpa are also reported for a number of pharmacological 
activities, including anti-tumor, anti-oxidant, anti-viral and 
vasodilator [4]. Nigella sativa is a plant originated in the 
Mediterranean region, but it has been cultivated in other area, such 
as Asia. Indonesia is a potential area for its growth due to the 
suitable tropical climate. N. sativa has been traditionally used as 
analgesic, anti-pyretic, anti-inflammatory and anti-microbial [5]. 
Study by Hendra, et al. resulted potent antioxidant and anti-
inflammatory activities of P. macrocarpa fruit extract through 
inhibition of nitric oxide (NO). A study held by Seif show potent anti-
inflammatory activities of N. sativa against osteoporosis via 
inhibition of COX activity [6]. Previous study result by 
Tjandrawinata et al. (2010) show anti-inflammatory activities of 
another Phaleria macrocarpa fraction, DLBS1425. It is an fraction of 
P. macrocarpa fruits which contains 20.26% phalerin. This fraction 
confers its anti-inflammatory effects by inhibiting COX-2 mRNA. 
Thereby causing a decreased in Prostaglandin (PGE) synthesis [7]. 
Another previous study confers its anti-cancer agent which targets 
genes involved in both cell survival and apoptosis in MDA-MB-231 
breast cancer cells [8]. 
In this present study, DLBS0533 which is combination of Phaleria 
macrocarpa and Nigella sativa was interesting to observe for 
potentially its anti-inflammatory activities. Carrageenan-induced 
paw edema in mice was chosen as the model study for inflammation.  
MATERIALS AND METHODS 
Test and control articles 
DLBS0533 was prepared by Dexa Laboratories of Biomolecular 
Sciences (Cikarang, Indonesia). DLBS0533 is extracted from a 
combination of two herbs, namely Nigella sativa seed and 
Phaleria macrocarpa fruits. Nigella sativa was purchased from 
Kulon Progo (Yogyakarta, Indonesia), while Phaleria macrocarpa 
was provided from Bantul (Yogyakarta, Indonesia). Nigella sativa 
seed and Phaleria macrocarpa fruits (1:3) were percolated using 
water. Extract was dried using evaporator at 45ºC. Dried fraction 
is named as DLBS0533 and analyzed by Thin Layer 
Chromatography (TLC), using Silica gel 60 F254 (Merck, USA) with 
mixed solvent ethyl acetate/acetone/formic acid/water (8:2:1:1). 
TLC resulted in two spot with Rf ±0.25 and Rf ±0.70 was 
examined under UV366 nm*. 
DLBS0533 was given at doses of 39, 78 and 156 mg/kg body weight 
(b. w.), which were equivalent to 300, 600 and 1200 mg/70 kg in 
human dose, respectively. Diclofenac potassium at dose of 9.1 mg/kg 
b. w.  was used as positive control in this study. Carrageenan 0.5% 
(w/v) was used to induce edema in mice. Distilled water was used as 
solvent and given as negative control.  
Test animals and housing 
Two untill three-month-old male Swiss mice (weighing 25-35 g) 
were obtained from Biological Laboratories, Faculty of Pharmacy, 
Sanata Dharma University, Jogjakarta. Animals were treated 
similarly with respect to the food, cage and drinking water. They 
were fed with standard rodent food and ad libitum drinking water. 
The room temperature was maintained at 22⁰C ± 3⁰C with relative 
humidity of 30% to 70%. The animals were exposed to 12 h-12 h 
light dark cycle. All experimental precedures for animal use have 
been approved with approval number KE/FK/613/EC by Medical 
and Health Research Ethics Committees, ministry of national 
education, Faculty of Medicine Gadjah Mada University. All 
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experimental animals were acclimatized for ± 2 weeks prior to the 
commencement of study. 
Study design 
Mice were randomly divided into positive control group, negative 
control and dose groups, consisting of 10 mice in each Mice were 
fasted for 24 hours before administration of DLBS0533, only 
drinking water was given ad libitum. Carrageenan-induced paw 
edema in mice was used as animal models. 0.5% Carrageenan was 
given via subplantar route to induce edema. Then, each group was 
treated orally with distilled water, diclofenac potassium and 
treatment dose of 39, 78 and 156 mg/kg b. w. DLBS0533, 
respectively. Measurement of edema was performed using calipers 
post-carrageenan induction and treatment. Edema thickness was 
examined every 30 minutes for 6 hours post-carrageenan induction 
edema (0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 
minutes). The calculation of the edema volume was conducted using 
formula as follows:   
 
Tu = Tt – To                           (1) 
Tu: Thickness of mice foot edema in particular time 
Tt: Thickness of mice foot after 0.5% carrageenan induction 
To: Thickness of mice foot before 0.5% carrageenan induction 
Area Under Curve (AUC) was calculated for each minute within 0-6 
hours using trapezoid method formula, as below:   
tn  Ttn-1 + Ttn 
        AUCtn-1 =    (tn – tn-1)                    (2) 
 
Ttn-1: Average edema volume on tn-1 
Ttn: Average edema volume on tn 
Percentage inhibition of inflammation was calculated according to 
the formula: 
 
                         (3) 
(AUC0-x)0 = average AUC0-x for negative control group, (AUC0-x)n = AUC0-x for each animal given test drug at dose of n. 
 
Statistical analyses 
Area Under Curve (AUC) was used to calculate percentage 
inhibition of inflammation (% reduction in edema). Statistical 
analyses was conducted between each treatment group to negative 
and positive control group. It was significantly different if p<0.05. 
The results were analyzed using Kolmogorov-Smirnov test, 
followed by ANOVA with 95% confidence interval. Scheffe test was 
used for significantly different results. GLM repeated measures test 
was performed to know the differences of edema thickness graph 
between each group. 
RESULTS 
Examination of edema thickness, AUC and percentage inhibition of 
inflammation were shown in table 1, 2 and 3 and also Fig. 1. Table 1. 
shows edema thickness during 6 hours of observation.  
Minute 0 represented paw edema thickness as a baseline after 
carrageenan induction and treatment. Fig. 1 is a graph of mean 
edema thickness during 6 hours of observation.  
Table 2 shows the calculation of AUC from edema thickness 
observed. Therefore, Table 3 shows the percentage inhibition of 
edema. This present study resulted in reduction of edema 27.26%, 
30.71% and 32.72% at dose of 39, 78 and 156 mg/kg b. w., of 
DLBS0533 respectively.  
The positive control group shows reduction 48.65% in edema. 
Statistical analyses between treatment dose groups to negative and 
positive control show that all dose groups gave significantly 
different with negative groups. Then, only dose of 156 mg/kg b. w. of 
DLBS0533 is not significantly different compared to diclofenac 
potassium at dose 9.1 mg/kg b. w. (Table 2 and table 3). 
  
Table 1: Mean edema thickness (mm) to time (minute) in anti-inflammatory effect using 0.5% carrageenan-induced mice animal model 
Treatment Average Edema Thickness (mm) on Minute 
0 30 60 90 120 150 180 210 240 270 300 330 360 
Negative control (Distilled water) 2.24 1.92 1.90 1.69 1.93 1.80 1.68 1.92 1.59 1.60 1.29 1.07 1.24 
Positive control (Diclofenac potassium 
9.1 mg/kg b. w.) 
0.39 0.64 0.67 0.83 1.10 1.49 0.89 1.23 0. 87 0.76 0.74 0.69 0.45 
DLBS0533 
39 mg/kg b. w. 
1.27 1.25 1.11 1.30 1.45 1.29 1.44 1.49 1.27 1.21 0.80 1.02 0.79 
DLBS0533 
78 mg/kg b. w. 
1.51 1.21 0.99 1.54 1.12 1.31 1.17 1.14 1.20 1.29 0.87 0.77 0.65 
DLBS0533 156 mg/kg b. w. 0.95 0.74 0.78 1.22 1.53 1.56 1.29 1.71 1.14 1.08 1.02 0.73 0.56 
Data depicted on both table 1 and Fig. 1 suggested that treatment of DLBS0533 in all dose group lead to reductions in paw edema thickness, thus 
signifying DLBS0533 as anti-inflammatory agent. This effect is pronouncedly depicted on Fig. 1 in which the downward trends of the line 
represented reduction in carrageenan-induced paw edema thickness in mice.  
 
 
Fig. 1: AUC Graph in Minute 0-360 in association between 
measurement time (minute) to mice paw thickness (mm) 
DISCUSSION 
This present study was conducted to assess the anti-inflammatory 
effect of DLBS0533 using carrageenan-induced mice. Carrageenan-
induced paw edema is a widely used test to determine anti-
inflammatory effect. It is a simple and routine animal model for 
evaluation in site of inflammation, without any injury or damaged to 
the paw edema [9]. Carrageenan also has been known to have 
sensitive response for inflammation [10]. 
Carrageenan, as irritant substances, induced cells injury through 
releases of mediators which cause inflammation. The development 
of carrageenan-induced edema is a biphasic event. The initial phase 
(after an hour) is associated to the release of serotonin, histamine 
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and bradykinin. The late phase (after an hour) is mainly due to the 
neutrophil infiltration into the inflammatory site and production of 
large amounts of pro-inflammatory mediators, such as 
prostaglandins (PGE) and various cytokines. The inflammatory 
edema reached its maximum level at the third hour and after that it 
started declining [11]. A previous study by Posadas et al. indicated 
that injection of carrageenan in the mouse paw caused a biphasic 
response:  an early inflammatory response that lasts for 6 hours 
and a second late response that peaks at 72 hours, declining at 96 
hours [12]. 
Previous study by Alemi et al. resulted that alcoholic extract of N. 
sativa seeds has an anti-inflammatory effects to rat’s neuronal cells 
[13]. Crude fix oil of N. sativa also shows inhibitory effect to COX and 
5-lipooxygenase (5-LO) pathways of arachidonate metabolism in rat 
peritoneal leukocytes. It also shows dose-dependent inhibition of 
thromboxane and leukotriene (LT) [14]. 
The most abundant and active component of N. sativa is 
thymoquinone (TQ). TQ is believed to exert anti-inflammatory 
effect by inhibiting 5-LO and LT synthesis in a dose-dependent 
manner [15]. N. sativa is also reported to contain phenolic. This 
compound has diverse physiological properties, including 
analgesic and anti-inflammatory activities [16]. Beside that 
previous study by Hendra et al. shows NO inhibitory effect of P. 
macrocarpa extract in a dose-dependent manner. The highest 
dose of the extract shows the highest inhibition percentage of 
NO [3]. NO is recognized as a mediator and regulator of 
inflammatory responses, and it is involved in several 
inflammatory disorders [17, 18]. Antioxidant and anti-
inflammatory activities of P. macrocarpa was due to the presence 
of flavonoids and phenolic compounds [3,19]. Flavonoid has 
been identified for its potential in inhibiting COX, thus it inhibits 
the formation of PGE [20]. Therefore, combination of P. 
macrocarpa and N. sativa need to study for its anti-inflammatory 
activities. 
 
Table 2: Mean AUC to time (minute) in anti-inflammatory effect in 0.5% carrageenan-induced mice animal model 





























9.1 mg/kg b. w.) 
15.51 19.71 22.61 29.06 38.88 35.72 31.85 31.49 24.48 22.62 21.48 17.07 310.46 
DLBS0533 
39 mg/kg b. w. 
37.77 35.39 36.11 41.28 41.10 40.88 43.98 41.54 37.29 30.14 27.26 27.09 439.80 
DLBS0533 
78 mg/kg b. w. 
40.76 32.91 37.91 39.90 36.44 37.28 38.81 39.18 37.37 32.37 24.63 21.45 418.98 
DLBS0533 156 
mg/kg b. w. 
25.35 22.80 30.09 41.25 46.38 42.86 44.99 42.71 33.27 31.46 26.28 19.37 406.79 
 
Table 3: Percentage inhibition of inflammation in 0.5% carrageenan-induced mice animal model 








Negative control (distilled 
water) 
604.64 0 - S 
Positive control (diclofenac 
potassium 9.1 mg/kg b. w.) 
310.46 48.65 S - 
DLBS0533 at dose of 39 mg/kg 
b. w.  
439.80 27.26 S S 
DLBS0533 at dose of 78 mg/kg 
b. w.  
418.98 30.71 S S 
DLBS0533 at dose of 156 mg/kg 
b. w.  
406.79 32.72 S NS 
S: Significantly different (p<0.05), NS: Not significantly different (p>0.05) 
 
Result of this study shows DLBS0533 has potentially inhibition of 
the inflammation activity (as anti-inflammatory). Since DLBS0533 is 
a bioactive fraction of combination between P. macrocarpa and N. 
sativa, it potentially contains thymoquinone, flavonoids and phenolic 
compound. Those combination compounds may have strong anti-
inflammatory activities.  
It resulted DLBS0533 at dose of 156 mg/kg b. w. gave the most 
potent anti-inflammatory effect and was not significantly different to 
positive control (diclofenac potassium) at dose of 9.1 mg/kg b. w. 
DLBS0533 at dose of 156 mg/kg b. w. where equivalent to 1200 
mg/70 kg human weight have a same effect in reduction in edema 
with diclofenac potassium 9.1 mg/kg b. w. where equivalent to 70 
mg/70 kg human weight. Therefore, DLBS0533 at dose 39 and 78 
mg/kg b. w. also gave anti-inflammatory activities that was shown in 
the percent inhibition of edema percentage inhibition of edema. This 
present study show DLBS0533 as anti-inflammatory agent. Further 
studies are required to establish the safety of DLBS0533 in animal 
and human models, followed by clinical trials to elucidate its effect in 
human patients.  
CONCLUSION 
In conclusion, result of the present study suggested that DLBS0533 has 
anti-inflammatory effect. DLBS0533 at dose 156 mg/kg b. w. (equivalent 
to human dose 1200 mg/70 kg b. w. human dose), may provide strong 
anti-inflammatory effect same as diclofenac potassium 9.1 mg/kg b. w. 
(equivalent to human dose 70 mg/70 kg b. w. human). 
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